Credit Suisse’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $154M | Buy |
1,615,396
+31,334
| +2% | +$2.63M | 0.15% | 120 |
|
|
2023
Q4 | $121M | Sell |
1,584,062
-86,124
| -5% | -$5.99M | 0.12% | 165 |
|
|
2023
Q3 | $116M | Buy |
1,670,186
+118,940
| +8% | +$9.56M | 0.12% | 168 |
|
|
2023
Q2 | $146M | Sell |
1,551,246
-39,517
| -2% | -$3.43M | 0.14% | 126 |
|
|
2023
Q1 | $132M | Sell |
1,590,763
-100,281
| -6% | -$7.88M | 0.13% | 156 |
|
|
2022
Q4 | $126M | Buy |
1,691,044
+45,374
| +3% | +$3.5M | 0.13% | 157 |
|
|
2022
Q3 | $136M | Sell |
1,645,670
-26,137
| -2% | -$2.51M | 0.15% | 132 |
|
|
2022
Q2 | $159M | Buy |
1,671,807
+13,618
| +0.8% | +$1.41M | 0.17% | 113 |
|
|
2022
Q1 | $195M | Buy |
1,658,189
+96,459
| +6% | +$10.8M | 0.17% | 113 |
|
|
2021
Q4 | $202M | Buy |
1,561,730
+108,577
| +7% | +$12.7M | 0.11% | 182 |
|
|
2021
Q3 | $165M | Sell |
1,453,153
-156,652
| -10% | -$17.9M | 0.09% | 217 |
|
|
2021
Q2 | $167M | Buy |
1,609,805
+125,041
| +8% | +$11.8M | 0.09% | 219 |
|
|
2021
Q1 | $124M | Buy |
1,484,764
+168,361
| +13% | +$14.2M | 0.06% | 331 |
|
|
2020
Q4 | $120M | Buy |
1,316,403
+159,010
| +14% | +$13.2M | 0.06% | 347 |
|
|
2020
Q3 | $92.4M | Sell |
1,157,393
-75,308
| -6% | -$5.88M | 0.06% | 368 |
|
|
2020
Q2 | $85.2M | Buy |
1,232,701
+128,047
| +12% | +$9.1M | 0.06% | 328 |
|
|
2020
Q1 | $69.5M | Sell |
1,104,654
-7,920
| -0.7% | -$571K | 0.06% | 309 |
|
|
2019
Q4 | $86.5M | Buy |
1,112,574
+188,742
| +20% | +$14.7M | 0.06% | 325 |
|
|
2019
Q3 | $67.7M | Sell |
923,832
-19,794
| -2% | -$1.39M | 0.06% | 348 |
|
|
2019
Q2 | $58.1M | Buy |
943,626
+180,843
| +24% | +$10.9M | 0.05% | 381 |
|
|
2019
Q1 | $48.6M | Sell |
762,783
-31,566
| -4% | -$1.8M | 0.04% | 437 |
|
|
2018
Q4 | $40.6M | Sell |
794,349
-158,190
| -17% | -$8M | 0.04% | 456 |
|
|
2018
Q3 | $55.3M | Sell |
952,539
-296,859
| -24% | -$14.5M | 0.05% | 384 |
|
|
2018
Q2 | $60.6M | Buy |
1,249,398
+44,967
| +4% | +$2.1M | 0.06% | 330 |
|
|
2018
Q1 | $56M | Sell |
1,204,431
-11,874
| -1% | -$516K | 0.05% | 377 |
|
|
2017
Q4 | $45.7M | Buy |
1,216,305
+53,985
| +5% | +$1.98M | 0.04% | 464 |
|
|
2017
Q3 | $42.4M | Sell |
1,162,320
-225,687
| -16% | -$8.61M | 0.04% | 468 |
|
|
2017
Q2 | $54.7M | Sell |
1,388,007
-291,348
| -17% | -$10.6M | 0.05% | 374 |
|
|
2017
Q1 | $52.7M | Buy |
1,679,355
+53,754
| +3% | +$1.68M | 0.05% | 414 |
|
|
2016
Q4 | $50.8M | Sell |
1,625,601
-25,500
| -2% | -$826K | 0.05% | 394 |
|
|
2016
Q3 | $66.4M | Sell |
1,651,101
-6,039
| -0.4% | -$227K | 0.06% | 324 |
|
|
2016
Q2 | $55.1M | Buy |
1,657,140
+19,758
| +1% | +$676K | 0.06% | 332 |
|
|
2016
Q1 | $48.1M | Buy |
1,637,382
+91,158
| +6% | +$2.52M | 0.06% | 355 |
|
|
2015
Q4 | $40.7M | Buy |
1,546,224
+600,762
| +64% | +$15.6M | 0.05% | 461 |
|
|
2015
Q3 | $22.4M | Sell |
945,462
-408,222
| -30% | -$9.85M | 0.03% | 676 |
|
|
2015
Q2 | $32.1M | Sell |
1,353,684
-358,602
| -21% | -$8.09M | 0.03% | 591 |
|
|
2015
Q1 | $40.7M | Buy |
1,712,286
+443,766
| +35% | +$9.96M | 0.04% | 504 |
|
|
2014
Q4 | $26.9M | Buy |
1,268,520
+79,596
| +7% | +$1.6M | 0.02% | 728 |
|
|
2014
Q3 | $20.2M | Buy |
1,188,924
+136,410
| +13% | +$2.15M | 0.02% | 905 |
|
|
2014
Q2 | $15.1M | Sell |
1,052,514
-103,242
| -9% | -$1.4M | 0.01% | 1114 |
|
|
2014
Q1 | $14.3M | Sell |
1,155,756
-304,122
| -21% | -$3.51M | 0.01% | 1019 |
|
|
2013
Q4 | $16M | Buy |
1,459,878
+196,620
| +16% | +$2.22M | 0.01% | 951 |
|
|
2013
Q3 | $14.7M | Sell |
1,263,258
-259,710
| -17% | -$3.04M | 0.01% | 917 |
|
|
2013
Q2 | $17.1M | Buy |
+1,522,968
| New | +$18M | 0.02% | 839 |
|
Other funds holding EW
Credit Suisse's EW Position: Q1 2024 in Review
Credit Suisse increased its Edwards Lifesciences (EW) stake by 2% in Q1 2024, buying an estimated $2.63M and bringing the position to 1,615,396 shares worth $154M. The position accounts for 0.15% of the portfolio, ranked #120.
Credit Suisse first reported a position in EW in Q2 2013 and has held it in 44 quarters since. The position peaked at $202M in Q4 2021. 1,279 funds tracked by Wall St. Rank hold EW as of Q1 2024.
- Credit Suisse held 1,615,396 shares of Edwards Lifesciences worth $154M as of Q1 2024.
- Credit Suisse bought 31,334 Edwards Lifesciences shares in Q1 2024, an estimated $2.63M.
- Edwards Lifesciences made up 0.15% of Credit Suisse's portfolio in Q1 2024, its #120 holding.
- Credit Suisse first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 44 quarters since.
- Credit Suisse's Edwards Lifesciences position peaked at $202M in Q4 2021.
- 1,279 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.